Furthermore, the combination of PD-1 blockade with ipilimumab demonstrated increased, durable anti-tumor activity in renal cell carcinoma and non-small cell lung cancer (NSCLC) (57, 58). The gene discussed is PDCD1; the disease is neoplasm.